WilmerHale Advises Visterra in $46.7M Series C Financing

WilmerHale Advises Visterra in $46.7M Series C Financing

Firm News

On October 5, 2017, Visterra, Inc., a clinical-stage biotechnology company that uses its novel HierotopeĀ® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches, announced that it has completed a Series C financing round raising a total of $46.7 million, including a new extension totaling $23.6 million.

The WilmerHale team representing Visterra in this transaction included Lia Der Marderosian, Molly Fox, Emily Gainor and Sam Rothberg.

Visterra's press release is available at www.visterrainc.com.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.